Paul Bastard - Infectious Diseases

Author Information

Paul Bastard is a researcher affiliated with the Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, located at Necker Hospital for Sick Children in Paris, EU, France. His work primarily focuses on the genetic and immunological aspects of infectious diseases, with a significant emphasis on the role of interferons in viral infections, particularly COVID-19.

Research Contributions

Paul Bastard has made substantial contributions to understanding the role of type I interferons in viral infections, with a focus on SARS-CoV-2. His research has identified autoantibodies that neutralize type I interferons in severe COVID-19 cases and investigated genetic predispositions to severe viral diseases. His work has also explored the immunological profiles and genetic abnormalities associated with critical COVID-19, multisystem inflammatory syndrome in children (MIS-C), and other infectious diseases.

Aliases

Paul Bastard is also known by the aliases P Bastard and P. Bastard. These variations may appear in different publications or databases.

Publication and Citation Metrics

Metric	Value
Citation Count	7347
H-index	35
Paper Count	117

Publications:

Type I interferons and SARS-CoV-2: from cells to organisms

DOI: 10.1016/j.coi.2022.01.003

Year: 2022

Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital

DOI: 10.1007/s10875-021-01203-3

Year: 2022

A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes.

DOI: 10.1084/jem.20220028

Year: 2022

TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C

DOI: 10.1084/jem.20211381

Year: 2022

Human autoantibodies underlying infectious diseases

DOI: 10.1084/jem.20211387

Year: 2022

Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort

DOI: 10.1126/scitranslmed.abj7521

Year: 2022

Neutralizing Type I Interferon Autoantibodies in Japanese Patients With Severe COVID-19

DOI: 10.21203/rs.3.rs-1430985/v1

Year: 2022

Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq

DOI: 10.1101/2022.03.23.485509

Year: 2022

Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome

DOI: 10.1007/s10875-022-01215-7

Year: 2022

Why do people die from COVID-19?

DOI: 10.1126/science.abn9649

Year: 2022

What Are the Complications of Herpes?

What are the Challenges in Studying Parasite DNA?

What Are Functional Assays?

How Do Decongestants Work?

What Are the Symptoms of Malaria?

What is the Scope of Infectious Diseases?

What are the Symptoms of Yellow Fever?

What is the impact of climate change on infectious diseases?

How Do Environmental Factors Influence These Interactions?

How Does the FDA Collaborate Internationally?

Partnered Content Networks

Relevant Topics